Evofem Biosciences Holds Annual Meeting, Approves Key Proposals
Ticker: EVFM · Form: 8-K · Filed: Jun 26, 2024 · CIK: 1618835
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting, filing-update
TL;DR
Evofem shareholders voted on directors and accounting firms; governance updates filed.
AI Summary
On June 20, 2024, Evofem Biosciences, Inc. filed an 8-K report detailing several key events. The company announced the results of its annual meeting of stockholders, including the election of directors and the ratification of its independent registered public accounting firm. Additionally, the filing disclosed material modifications to the rights of security holders and amendments to its articles of incorporation.
Why It Matters
This filing provides an update on corporate governance and shareholder decisions, which can impact investor confidence and the company's strategic direction.
Risk Assessment
Risk Level: low — The filing primarily concerns routine corporate governance matters and shareholder votes, with no immediate financial distress or significant operational changes indicated.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- June 20, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 20-8527075 (identifier) — I.R.S. Employer Identification No.
FAQ
What were the main outcomes of Evofem Biosciences' annual meeting of stockholders on June 20, 2024?
The filing indicates that the annual meeting involved the election of directors and the ratification of the company's independent registered public accounting firm.
What specific items were voted on by Evofem Biosciences' security holders?
The filing mentions the submission of matters to a vote of security holders, including the election of directors and the ratification of the independent registered public accounting firm.
Were there any material modifications to the rights of Evofem Biosciences' security holders?
Yes, the filing explicitly lists 'Material Modifications to Rights of Security Holders' as an item of disclosure.
Did Evofem Biosciences amend its articles of incorporation or bylaws?
Yes, the filing indicates 'Amendments to Articles of Incorporation or Bylaws' as a reported item.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 20, 2024.
Filing Stats: 642 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2024-06-26 16:46:23
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share EVFM OTCQB Indicate by
- $0.0154 — ion and changed the Conversion Price to $0.0154 as described in Section 4(b)(ii). Follo
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex3-1.htm (EX-3.1) — 329KB
- 0001493152-24-025289.txt ( ) — 611KB
- evfm-20240620.xsd (EX-101.SCH) — 3KB
- evfm-20240620_lab.xml (EX-101.LAB) — 34KB
- evfm-20240620_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Dated: June 26, 2024 By: /s/ Saundra Pelletier Sandra Pelletier Chief Executive Officer